+検索条件
-Structure paper
タイトル | A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. |
---|---|
ジャーナル・号・ページ | Cell Host Microbe, Vol. 29, Issue 5, Page 806-818.e6, Year 2021 |
掲載日 | 2021年5月12日 |
著者 | Hejun Liu / Meng Yuan / Deli Huang / Sandhya Bangaru / Fangzhu Zhao / Chang-Chun D Lee / Linghang Peng / Shawn Barman / Xueyong Zhu / David Nemazee / Dennis R Burton / Marit J van Gils / Rogier W Sanders / Hans-Christian Kornau / S Momsen Reincke / Harald Prüss / Jakob Kreye / Nicholas C Wu / Andrew B Ward / Ian A Wilson / |
PubMed 要旨 | Coronaviruses have caused several human epidemics and pandemics including the ongoing coronavirus disease 2019 (COVID-19). Prophylactic vaccines and therapeutic antibodies have already shown striking ...Coronaviruses have caused several human epidemics and pandemics including the ongoing coronavirus disease 2019 (COVID-19). Prophylactic vaccines and therapeutic antibodies have already shown striking effectiveness against COVID-19. Nevertheless, concerns remain about antigenic drift in SARS-CoV-2 as well as threats from other sarbecoviruses. Cross-neutralizing antibodies to SARS-related viruses provide opportunities to address such concerns. Here, we report on crystal structures of a cross-neutralizing antibody, CV38-142, in complex with the receptor-binding domains from SARS-CoV-2 and SARS-CoV. Recognition of the N343 glycosylation site and water-mediated interactions facilitate cross-reactivity of CV38-142 to SARS-related viruses, allowing the antibody to accommodate antigenic variation in these viruses. CV38-142 synergizes with other cross-neutralizing antibodies, notably COVA1-16, to enhance neutralization of SARS-CoV and SARS-CoV-2, including circulating variants of concern B.1.1.7 and B.1.351. Overall, this study provides valuable information for vaccine and therapeutic design to address current and future antigenic drift in SARS-CoV-2 and to protect against zoonotic SARS-related coronaviruses. |
リンク | Cell Host Microbe / PubMed:33894127 / PubMed Central |
手法 | EM (単粒子) / X線回折 |
解像度 | 1.53 - 31.0 Å |
構造データ | EMDB-23469: EMDB-23470: EMDB-23471: EMDB-23472: PDB-7lm8: PDB-7lm9: |
化合物 | ChemComp-EDO: ChemComp-HOH: |
由来 |
|
キーワード | VIRAL PROTEIN/IMMUNE SYSTEM (ウイルス性) / SARS-CoV-2 (SARSコロナウイルス2) / SARS-CoV (SARSコロナウイルス) / Antibody (抗体) / Spike / Coronavirus (オルトコロナウイルス亜科) / COVID-19 (新型コロナウイルス感染症 (2019年)) / SARS (重症急性呼吸器症候群) / IMMUNE SYSTEM (免疫系) / VIRAL PROTEIN-IMMUNE SYSTEM complex (ウイルス性) / Cross-Neutralization / Synergy (相乗効果) / VIRAL PROTEIN (ウイルスタンパク質) |